Leary, A;
Tan, D;
Ledermann, J;
(2021)
Immune checkpoint inhibitors in ovarian cancer: where do we stand?
Therapeutic Advances in Medical Oncology
, 13
10.1177/17588359211039899.
Preview |
Text
Immune checkpoint inhibitors in ovarian cancer.pdf - Published Version Download (360kB) | Preview |
Abstract
Numerous retrospective studies have demonstrated that the density of intra-tumoral immune cell infiltration is prognostic in epithelial ovarian cancer (OC). These observations together with reports of programmed death ligand-1 (PD-L1) expression in advanced OC provided the rationale for investigating the benefit of programmed death-1 (PD1) or PD-L1 inhibition in OC. Unfortunately clinical trials to date evaluating PD1/PD-L1 inhibition in patients with relapsed OC have been disappointing. In this review we will discuss early results from single agent PD1/PD-L1 inhibitors and the strategies to enhance benefit from immune-oncology agents in OC, including proposing anti-PD-L1 in combination with other agents (cytotoxics, anti-angiogenics, poly(ADP-ribose) polymerase. (PARP) inhibitors, targeted therapies or other immunotherapies), as well as evaluating these agents earlier in the disease course, or in biomarker selected patients.
| Type: | Article |
|---|---|
| Title: | Immune checkpoint inhibitors in ovarian cancer: where do we stand? |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1177/17588359211039899 |
| Publisher version: | https://doi.org/10.1177/17588359211039899 |
| Language: | English |
| Additional information: | This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| Keywords: | Anti-angiogenic, combinations, immune checkpoint inhibitors, ovarian cancer, PARP inhibitors, predictive biomarkers |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > CRUK Cancer Trials Centre |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10133805 |
Archive Staff Only
 |
View Item |
